GLP-1 receptor agonists consistently reduce BMI and body weight in adolescents with obesity, with newer trials extending to children as young as 6, but critical gaps remain in pediatric dosing, long-term safety, and effects on growth and development.
Ages 6+ now in trialsGLP-1 agonist trials are extending from adolescents to children as young as 6, but long-term developmental safety data are still missing
What the researchers found
Liraglutide and semaglutide consistently produced clinically meaningful reductions in BMI, body weight, and waist circumference in adolescents with obesity, with modest improvements in systolic blood pressure and minimal effects on lipid levels or HbA1c. Newer trials have begun evaluating GLP-1RAs in children aged 6 and older.
Critical knowledge gaps include pediatric pharmacokinetics, optimal dosing strategies, long-term developmental safety (particularly musculoskeletal health), nutritional adequacy during rapid weight loss in growing children, and the risk of misuse. The review concludes that pediatric-specific protocols are essential to safely translate adult GLP-1 agonist success to younger populations.
Why it matters
Childhood obesity affects over 340 million children worldwide and is a major driver of early-onset type 2 diabetes, heart disease, and psychological harm. While GLP-1 drugs show clear efficacy, children are not small adults — their growing bodies have different nutritional needs, and rapid weight loss during development could have consequences not seen in adult trials. Getting this right is critical as prescriptions for children surge.
How the study worked
Structured review of randomized controlled trials, extension studies, and mechanistic investigations evaluating GLP-1 receptor agonists in pediatric obesity and type 2 diabetes. Outcomes assessed included body weight, BMI, body composition, glycemic control, and adverse events.
What this study cannot tell us
This is a structured review, not a systematic review or meta-analysis. Most RCT data comes from adolescents (12+), with very limited data in younger children. Long-term follow-up beyond 1-2 years is largely unavailable. Effects on musculoskeletal development, puberty, and final adult height are unknown. The review acknowledges significant gaps in pediatric pharmacokinetics and optimal dosing.
How to read the evidence
This review synthesizes evidence from RCTs and extension studies in adolescents, with emerging data in younger children. The evidence for efficacy is strong in adolescents, but data in younger children is limited, and long-term developmental safety has not been established.
When this study was published
Published in 2025, this is a very current review capturing the rapid expansion of GLP-1 agonist use into pediatric populations — a topic of intense clinical and public interest.
The bigger picture
The use of GLP-1 agonists in children represents one of the most consequential expansions of this drug class. With childhood obesity rates at historic highs and few effective pharmacological options, these drugs fill an urgent need. However, the rush to treat must be balanced against the reality that we are prescribing weight-altering medications to developing bodies with decades of life ahead — making long-term safety data especially critical.
Questions still open
- Does GLP-1 agonist-induced weight loss during childhood affect final adult height, bone density, or muscle development?
- What is the appropriate minimum age for GLP-1 agonist treatment in childhood obesity, and how should dosing differ from adults?
- What safeguards can prevent misuse of GLP-1 agonists in children who do not have clinical obesity?
Common questions
Are GLP-1 drugs safe for children?
Why can't you just give children the same dose as adults?
Read the original research
Beyond Weight Loss: Optimizing GLP-1 Receptor Agonist Use in Children.
Children (Basel, Switzerland), 12(11)
Citation
Zaitoon, Hussein; Wauters, Aimee D; Rodriguez, Luisa M; Lynch, Jane L. (2025). Beyond Weight Loss: Optimizing GLP-1 Receptor Agonist Use in Children.. Children (Basel, Switzerland), 12(11). https://doi.org/10.3390/children12111427